Navigation Links
Barnett Releases Reference Guide on Form FDA 1572--Statement of Investigator

Barnett International, a division of Cambridge Healthtech Institute (CHI), has announced the release of The Form FDA 1572: A Reference Guide for Clinical Researchers, Sponsors, and Monitors. Designed for clinical investigators, clinical site staff, study monitors, regulatory affairs professionals, and others involved in the clinical research process, the text is the first reference guide to address the Form FDA 1572-Statement of Investigator form, a critical regulatory document that well over 20,000 clinical investigators complete and sign each year before participating in FDA-regulated clinical trials.

Needham, MA (PRWEB) October 11, 2008 -- The Form FDA 1572: A Reference Guide for Clinical Researchers, Sponsors, and Monitors addresses an emerging reality in clinical research today: As the number of FDA-issued warning letters to clinical investigators has risen in recent years, so too have citations regarding investigators' failure to complete the 1572 appropriately and correctly.

This new, state-of-the-art reference guide was developed to help not only experienced clinical investigators, who continue to struggle with addressing emerging trial-related complexities of modern clinical trials in the 1572, but the growing number of investigators who are conducting their first FDA-regulated trials each year. In addition to the FDA's emerging expectations regarding the 1572, the new reference guide directly addresses new 1572-related challenges facing clinical investigators and industry trial sponsors, including: the implications of what the FDA calls the "dispersing of study functions;" Norway's recent ban against the 1572; the evolution of the "subinvestigator" concept; and the increasing role of non-U.S. clinical investigators in FDA-regulated clinical trials.

The Form FDA 1572 reference guide addresses the most often-asked--but never answered--questions and also explores emerging areas of uncertainty related to the growing complexity of today's clinical trials, including:

  • When must a non-US clinical investigator sign a 1572?
  • How can a clinical investigator determine when a member of the site staff should be identified as a "subinvestigator"?
  • What are the legal/regulatory implications of signing a 1572--is it a legal contract?
  • When can a sponsor consider a clinical investigator to meet the "appropriate expert" standard?
  • What do we do now that at least one foreign country has banned the use of the 1572 for its clinical investigators?
  • How should "co-investigators" be handled in the 1572?
  • Must clinical investigators sign 1572s for "satellite sites"?
  • What must a study sponsor do beyond "collecting the paper" in the 1572 process?

The Form FDA 1572: A Reference Guide for Clinical Researchers, Sponsors, and Monitors is available from Barnett Educational Services for $45 per copy (bulk discounts available) by calling 1-800-856-2556 or click here to order your copy today.

About Barnett International
Barnett International is a recognized leader in clinical education and training for all levels of staff involved in the drug development process. In addition, Barnett is the publisher of the GCP Q&A Guide, the PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook, and other well-known reference manuals that help research facilities ensure compliance by providing updates about the latest federal regulations, while offering executives valuable information garnered from real-world studies, analyses, and widely respected industry opinion leaders. For more information on Barnett's publications and educational programs, visit

About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI) ( is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, Pharmaceutical Strategy Series, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech's Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Downtown Emergency Service Center Releases CHASERS, Free Software for Homeless Service Management and Beyond
2. USP releases first certified reference material
3. change:healthcare CEO Releases 'My Healthcare is Killing Me'
4. AHRQ Releases Two New Resources to Help Consumers and Clinicians Prevent Dangerous Blood Clots
5. Sodexo Releases Innovative Prepaid Incentive Card Powered by eCommLink
6. Z Trim Holdings, Inc. Releases Letter to Shareholders
7. Mindray Releases Historical Financial Results Converted into US Dollar Terms
8. Pennsylvania Trauma Systems Foundation Releases Data Supporting Mandatory Use of Motorcycle Helmets
9. URAC Releases Revised Standards For Nine Health Care Management Accreditation Programs
10. ABC Releases Monograph on Scientific Research of POM Wonderful(R) Pomegranate Juice
11. ProSanos Corporation Releases New Software System to Improve Patient Safety via Surveillance and Analysis of Claims and Electronic Health Records
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... The Multiple System Atrophy Coalition has announced the launch of ... (MSA) research, timed today to coincide with Giving Tuesday 2015, a global day of ... to work and be productive, to do simple daily activities like walking to the ...
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, ... expansion of the company’s growing product line of food safety and seafood fraud ... Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015   MabVax Therapeutics Holdings, Inc . ... it has filed an Investigational New Drug Application (IND) ... the Company,s lead fully human antibody product HuMab 5B1 ... plans to initiate the Phase I clinical trial early ... --> The planned Phase I trial will evaluate ...
(Date:12/1/2015)... , Dec. 1, 2015   Craneware, Inc ... cycle solutions, today announced the company will showcase ... ChargeLink ® solution at the American ... Clinical Meeting . The new features are focused ... of monitoring and managing enterprise-wide pharmacy charges to ...
(Date:12/1/2015)... , Dec. 01, 2015 ... of the "Medical Alert Systems/Personal Emergency Response ... by Geography - Global Forecas" report to ... announced the addition of the "Medical Alert ... by End-User and by Geography - Global Forecas" ...
Breaking Medicine Technology: